Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
pharmaphorum1d
BMS' Opdivo stumbles in lung cancer, but could still maintain lead
Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...
pharmaphorum6d
NICE says lung cancer breakthrough Opdivo too expensive
BMS's Opdivo has been rejected by NICE for use in patients with advanced lung cancer, the cost-effectiveness watchdog saying its price is too high to merit routine use.
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
Le Lézard4d
Reflections Achieves ISO 42001:2023 Certification for Responsible AI Management
Reflections Info Systems (sister concern of Reflections Systems Inc.), a leading technology innovation services provider, has announced that it has achieved ISO 42001:2023 certification, awarded ...
Le Lézard5m
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...
inkbotdesign.com3d
Top 20 Fashion Logos: Best Designs in the Industry
Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...